908 Devices (MASS) 17th Annual Midwest IDEAS Conference summary

Strategic transformation and financial performance

• Shifted focus to handheld chemical detection and analysis, reporting 23% YoY revenue growth in Q2 2026, with $16.1 million in quarterly revenue, $101.5 million in cash, and no debt.

• Divested bioprocessing desktop portfolio in 2025 to concentrate on public health, safety, and defense applications.

• Recurring revenues now represent 31–35% of the mix, with NIRLab expected to push this to ~50% in 2026.

• Raised 2026 revenue guidance to $68–$70 million, targeting 21–25% growth, with continued gross margin expansion and improving cost leverage.

• Maintains a strong balance sheet, supporting growth and tuck-in acquisitions like NIRLab without needing additional capital.

Market drivers and product innovation

• Macro tailwinds include the opioid crisis, rising global defense budgets, and increased border security funding, driving demand for modern detection tools.

• Product suite covers trace analytes, VOC gases, and bulk compounds, with integrated cloud-based software, 24/7 expert support, and AI-driven analytics.

• NIRLab acquisition expands recurring revenue and enables rapid frontline screening, with over 100 active customers and >99% retention.

• Regulatory shifts away from colorimetric test kits toward connected, auditable technology create durable demand for subscription-based solutions.

• Innovation pipeline includes OEM partnerships and integrations for industrial, pharma, drones, and unmanned vehicles.

Customer impact and use cases

• Devices are used by fire, hazmat, law enforcement, federal, and military agencies globally for narcotics, toxic chemicals, and industrial safety, with over 18,000 trained users.

• Real-world impact includes Virginia's Operation FREE, which reduced fatal overdoses in correctional facilities to zero, and a $6 million Asia-Pacific order for ProtectIR devices.

• Cloud connectivity enables fleet management, usage tracking, and trend analysis, with AI-powered guidance being integrated.

• Workshops, training, and grant support drive awareness and adoption among state and local agencies.

• Data aggregation and network effects from connected devices enable rapid response to emerging threats, such as new synthetic opioids.